サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1193120

創薬アウトソーシング市場：ワークフロー別、治療領域別、薬剤タイプ別、エンドユーザー別：世界機会分析および産業予測、2021-2031年

Drug Discovery Outsourcing Market By Workflow, By Therapeutic area, By Drug Type, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 251 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
創薬アウトソーシング市場：ワークフロー別、治療領域別、薬剤タイプ別、エンドユーザー別：世界機会分析および産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 251 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

創薬アウトソーシングの世界市場規模は、2021年に36億米ドル、2031年には74億米ドルに達し、2022年から2031年にかけてCAGR7.5％で成長すると予測されています。

創薬アウトソーシングは、さまざまな企業が業務の一部を外部のサプライヤーに移管することによって、医薬品開発のコストを削減するために利用する手法と定義されています。創薬から製品化まで、さまざまな分野でアウトソーシングが行われています。医薬品の商業化を専門とする第三者機関にアウトソーシングすることで、医薬品の価値提案を最大化することができます。薬理学、製薬、バイオテクノロジーなどさまざまな分野で、新しい医薬品や薬剤を発見するための手順です。

さらに、創薬受託研究機関（CRO）は、製薬企業やバイオテクノロジー企業に対して、創薬のための様々な研究サービスを受託しています。製薬会社は現在、医薬品開発の期間とコストを削減するために、研究開発活動を民間の開発業務受託機関（CRO）や学術研究機関にアウトソーシングしています。

がん、循環器疾患、糖尿病、高血圧などの慢性疾患の増加、創薬のための研究開発活動の増加、標的薬物療法の需要の急増などが、創薬アウトソーシング市場の成長を促進する主な要因となっています。例えば、IQVIAが2022年6月に発表したレポートによると、がん領域の医薬品開発における試験数は2016年に56％と歴史的な高水準に達しています。2021年に世界で初めて発売されたがん領域の新規活性物質は過去最高の30種類で、2012年以降では合計159種類が発売されています。したがって、研究活動数の増加は、市場で新しい分子を発売するために臨床試験を行う需要を増加させ、アウトソーシングサービスプロバイダーの需要を増加させ、したがって、市場の成長を後押しします。

さらに、製薬会社によるアウトソーシングサービスの採用の増加や、新薬の発売に向けたCROとしての主要プレイヤーの増加も、市場の成長を後押しすると予想されます。例えば、米国と欧州には1,000社を超えるCROが存在します。上位10社で業界売上高の約40%を占めています。しかし、CROは新薬の市場投入を効果的に早めることができる医薬品開発・臨床試験支援に重点を置いてきました。

しかし、コストが高いだけでなく、薬剤の失敗のリスクも高く、熟練した専門家の不足が市場の成長を妨げています。一方、がん、遺伝性疾患、慢性疾患の増加、高齢者人口の増加、良好な規制環境、新興国における高品質なデータを持つ低コストの熟練労働者の利用が、予測期間中の市場成長に有利な機会を提供すると期待されています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 創薬アウトソーシング市場：ワークフロー別

  • 概要
    • 市場規模および予測
  • ターゲット同定とスクリーニング
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • ターゲットバリデーションとファンクショナルインフォマティクス
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • リードの特定と候補の最適化
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 前臨床開発
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第5章 創薬アウトソーシング市場：治療領域別

  • 概要
    • 市場規模・予測
  • 呼吸器系
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 感染症
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • オンコロジー
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 免疫学
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 血液学
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 循環器領域
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 中枢神経系（CNS）
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 消化器系
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第6章 創薬アウトソーシング市場：薬剤タイプ別

  • 概要
    • 市場規模および予測
  • 低分子医薬品
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 大型分子
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第7章 創薬アウトソーシング市場：エンドユーザー別

  • 概要
    • 市場規模・予測
  • 製薬企業、バイオテクノロジー企業
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 学術機関
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第8章 創薬アウトソーシング市場：地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米市場規模・予測：ワークフロー別
    • 北米市場規模・予測：治療領域別
    • 北米市場規模・予測：薬剤タイプ別
    • 北米市場規模・予測：エンドユーザー別
    • 北米市場規模・予測：国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測：ワークフロー別
    • 欧州市場規模・予測：治療領域別
    • 欧州市場規模・予測：薬剤タイプ別
    • 欧州市場規模・予測：エンドユーザー別
    • 欧州市場規模・予測：国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他欧州
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測：ワークフロー別
    • アジア太平洋地域の市場規模・予測：治療領域別
    • アジア太平洋地域の市場規模・予測：薬剤タイプ別
    • アジア太平洋地域の市場規模・予測：エンドユーザー別
    • アジア太平洋地域の市場規模・予測：国別
      • 日本
      • 中国
      • オーストラリア
      • インド
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測：ワークフロー別
    • LAMEAの市場規模・予測：治療領域別
    • LAMEAの市場規模・予測：薬剤タイプ別
    • LAMEAの市場規模・予測：エンドユーザー別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第9章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第10章 企業プロファイル

  • . Charles River Laboratories,
  • Curia Global Inc
  • Dr. Reddy's Laboratories
  • Dalton Pharma Service
  • Discover X Corporation
  • Laboratory Corporation of America Holdings
  • Merck & Co
  • Syngene International Ltd
  • Thermo Fisher Scientific, Inc.
  • TCG Life Science Pvt. Ltd
図表

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. DRUG DISCOVERY OUTSOURCING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. UK DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. UK DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. UK DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. UK DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 96. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 97. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 98. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 99. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 100. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 101. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 102. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 103. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 104. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 105. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 106. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 107. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 108. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 109. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 110. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 111. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 112. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 113. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 114. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 115. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 116. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 117. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 118. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 119. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 120. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 121. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 122. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 123. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 124. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 125. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 126. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 127. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 128. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 129. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 130. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 131. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 132. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 133. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 134. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 135. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 136. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 137. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 138. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 139. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 140.. CHARLES RIVER LABORATORIES,: COMPANY SNAPSHOT
  • TABLE 141.. CHARLES RIVER LABORATORIES,: OPERATING SEGMENTS
  • TABLE 142.. CHARLES RIVER LABORATORIES,: PRODUCT PORTFOLIO
  • TABLE 143.. CHARLES RIVER LABORATORIES,: NET SALES
  • TABLE 144.. CHARLES RIVER LABORATORIES,: KEY STRATERGIES
  • TABLE 145.CURIA GLOBAL INC: COMPANY SNAPSHOT
  • TABLE 146.CURIA GLOBAL INC: OPERATING SEGMENTS
  • TABLE 147.CURIA GLOBAL INC: PRODUCT PORTFOLIO
  • TABLE 148.CURIA GLOBAL INC: NET SALES
  • TABLE 149.CURIA GLOBAL INC: KEY STRATERGIES
  • TABLE 150.DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT
  • TABLE 151.DR. REDDY'S LABORATORIES: OPERATING SEGMENTS
  • TABLE 152.DR. REDDY'S LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 153.DR. REDDY'S LABORATORIES: NET SALES
  • TABLE 154.DR. REDDY'S LABORATORIES: KEY STRATERGIES
  • TABLE 155.DALTON PHARMA SERVICE: COMPANY SNAPSHOT
  • TABLE 156.DALTON PHARMA SERVICE: OPERATING SEGMENTS
  • TABLE 157.DALTON PHARMA SERVICE: PRODUCT PORTFOLIO
  • TABLE 158.DALTON PHARMA SERVICE: NET SALES
  • TABLE 159.DALTON PHARMA SERVICE: KEY STRATERGIES
  • TABLE 160.DISCOVER X CORPORATION: COMPANY SNAPSHOT
  • TABLE 161.DISCOVER X CORPORATION: OPERATING SEGMENTS
  • TABLE 162.DISCOVER X CORPORATION: PRODUCT PORTFOLIO
  • TABLE 163.DISCOVER X CORPORATION: NET SALES
  • TABLE 164.DISCOVER X CORPORATION: KEY STRATERGIES
  • TABLE 165.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
  • TABLE 166.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
  • TABLE 167.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 168.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES
  • TABLE 169.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
  • TABLE 170.MERCK & CO: COMPANY SNAPSHOT
  • TABLE 171.MERCK & CO: OPERATING SEGMENTS
  • TABLE 172.MERCK & CO: PRODUCT PORTFOLIO
  • TABLE 173.MERCK & CO: NET SALES
  • TABLE 174.MERCK & CO: KEY STRATERGIES
  • TABLE 175.SYNGENE INTERNATIONAL LTD: COMPANY SNAPSHOT
  • TABLE 176.SYNGENE INTERNATIONAL LTD: OPERATING SEGMENTS
  • TABLE 177.SYNGENE INTERNATIONAL LTD: PRODUCT PORTFOLIO
  • TABLE 178.SYNGENE INTERNATIONAL LTD: NET SALES
  • TABLE 179.SYNGENE INTERNATIONAL LTD: KEY STRATERGIES
  • TABLE 180.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 181.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 182.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 183.THERMO FISHER SCIENTIFIC, INC.: NET SALES
  • TABLE 184.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
  • TABLE 185.TCG LIFE SCIENCE PVT. LTD: COMPANY SNAPSHOT
  • TABLE 186.TCG LIFE SCIENCE PVT. LTD: OPERATING SEGMENTS
  • TABLE 187.TCG LIFE SCIENCE PVT. LTD: PRODUCT PORTFOLIO
  • TABLE 188.TCG LIFE SCIENCE PVT. LTD: NET SALES
  • TABLE 189.TCG LIFE SCIENCE PVT. LTD: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION
  • FIGURE 2.DRUG DISCOVERY OUTSOURCING MARKET,2021-2031
  • FIGURE 3.DRUG DISCOVERY OUTSOURCING MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.DRUG DISCOVERY OUTSOURCING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.DRUG DISCOVERY OUTSOURCING MARKET,BY WORKFLOW,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TARGET IDENTIFICATION AND SCREENING DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGET VALIDATION AND FUNCTIONAL INFORMATICS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PRECLINICAL DEVELOPMENT DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 18.DRUG DISCOVERY OUTSOURCING MARKET,BY THERAPEUTIC AREA,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF RESPIRATORY SYSTEM DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INFECTIOUS DISEASE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF IMMUNOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HEMATOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 28.DRUG DISCOVERY OUTSOURCING MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF SMALL MOLECULES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF LARGE MOLECULES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 31.DRUG DISCOVERY OUTSOURCING MARKET,BY END USER,2021(%)
  • FIGURE 32.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 33.COMPARATIVE SHARE ANALYSIS OF ACADEMIC INSTITUTES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 34.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 35.DRUG DISCOVERY OUTSOURCING MARKET BY REGION,2021
  • FIGURE 36.U.S. DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 37.CANADA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 38.MEXICO DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 39.GERMANY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 40.FRANCE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 41.UK DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 42.ITALY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 43.SPAIN DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 44.REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 45.JAPAN DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 46.CHINA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 47.AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 48.INDIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 49.SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 50.REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 51.BRAZIL DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 52.SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 53.SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 54.REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 55. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 58.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 59.COMPETITIVE DASHBOARD
  • FIGURE 60.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 61.. CHARLES RIVER LABORATORIES,.: NET SALES ($MILLION)
  • FIGURE 62.CURIA GLOBAL INC.: NET SALES ($MILLION)
  • FIGURE 63.DR. REDDY'S LABORATORIES.: NET SALES ($MILLION)
  • FIGURE 64.DALTON PHARMA SERVICE.: NET SALES ($MILLION)
  • FIGURE 65.DISCOVER X CORPORATION.: NET SALES ($MILLION)
  • FIGURE 66.LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES ($MILLION)
  • FIGURE 67.MERCK & CO.: NET SALES ($MILLION)
  • FIGURE 68.SYNGENE INTERNATIONAL LTD.: NET SALES ($MILLION)
  • FIGURE 69.THERMO FISHER SCIENTIFIC, INC..: NET SALES ($MILLION)
  • FIGURE 70.TCG LIFE SCIENCE PVT. LTD.: NET SALES ($MILLION)
目次
Product Code: A14914

The global Drug Discovery Outsourcing Market Size was valued at $3.6 billion in 2021 and is projected to reach $7.4 billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031.. Drug discovery outsourcing is defined as a practice that is used by different companies to reduce the cost of drug development by transferring portions of work to outside suppliers. Outsourced activities can be carried out in various fields, right from drug discovery to the manufacturing of products. Outsourcing drug commercialization to a third-party service provider specializing in drug commercialization helps to ensure the maximization of a drug product's value proposition.  It is a procedure that is used to find new medicines or drugs in different fields such as pharmacology, pharmaceuticals, and biotechnology.

Moreover, drug discovery contract research organizations (CROs) are engaged in offering a range of research services on a contract basis to pharmaceutical and biotechnology companies for drug discovery. Pharmaceutical companies are now outsourcing their R&D activities to private contract research organizations (CROs) and academic research institutions to reduce drug development time and cost.

The key factors that drive the growth of the market are the rise in the prevalence of chronic diseases such as cancer, cardiovascular disease, diabetes, and high blood pressure; the increase in R&D activities for drug discovery, and the surge in demand for target drug therapy are the major factors that drive the growth of the drug discovery outsourcing market. For instance, according to the report published by IQVIA in June 2022, the number of trials in oncology drug development reached a historic high of 56% in 2016.  A record 30 oncology novel active substances were initially launched globally in 2021, and a total of 159 have been launched since 2012. Thus, the rise in the number of research activities increases the demand for performing clinical trials to launch new molecules in the market, which increases the demand for outsourcing service providers and hence boosts the growth of the market.

Furthermore, rise in the adoption of outsourcing services by pharmaceutical companies and the increase in the number of key players as CROs for the launch of novel drug therapies are anticipated to fuel the growth of the market. For instance, there are more than 1,000 CROs in the U.S. and Europe. The top 10 accounts for approximately 40% of industry sales. However, CROs have been focused on drug development and clinical trial support, where they can effectively speed the launch of a new drug in the market.

However, the high cost as well as the high risk of drug failure, along with the lack of skilled professionals, hamper the market's growth. Conversely, rising cases of cancer, genetic disease, & chronic disease; large geriatric population; a favorable regulatory environment; and the availability of low-cost skilled manpower with high-quality data in the developing countries are expected to provide a lucrative opportunity for the growth of the market during the forecast period. 

The drug discovery outsourcing market is segmented on the basis of workflow, therapeutic area, drug type, end user, and region. By workflow, it is fragmented into target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and others. By therapeutic area, it is classified into the respiratory system, infectious disease, oncology, immunology, hematology, cardiovascular, central nervous system, gastrointestinal, and others. By drug type, it is bifurcated into small molecules and large molecules. By end user, the market is categorized into pharmaceutical & biotechnology companies, academic institutes, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the drug discovery outsourcing market share in 2021 and is anticipated to remain dominant during the forecast period. The drug discovery outsourcing market is mainly driven by the presence of well-established research facilities and a high prevalence rate of cancer & chronic diseases. Moreover, the availability of technologically advanced medical devices and the rise in the demand for target drug therapy techniques to cure cancer are contributing to the growth of the market in this region. Furthermore, an increasing number of key players involved in R&D activities for the discovery of novel drugs is expected to fuel market growth.

Asia-Pacific is expected to register the fastest CAGR during the forecast period. This is due to the availability of low-cost skilled manpower and high-quality clinical trial data and constantly improving healthcare infrastructure. In addition, the rapidly growing population, rising incidence of cancer & chronic disease, and improvement in the quality of healthcare facilities are set to drive the market in Asia-Pacific. This helps several key market players to invest in Asia-Pacific countries, which in turn, is further expected to contribute to the growth of the market.

The key players that operate in the drug discovery outsourcing market are Curia Global Inc, Charles River Laboratories Inc, Dr. Reddy's Laboratories, Discover X Corporation, Dalton Pharma Service, Laboratory Corporation of America Holdings, Merck & Co, Syngene International Ltd, TCG Life Science Pvt. Ltd, and Thermo Fisher Scientific.

Key Benefits For Stakeholders 

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the drug discovery outsourcing market analysis from 2021 to 2031 to identify the prevailing drug discovery outsourcing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the drug discovery outsourcing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes an analysis of the regional as well as global drug discovery outsourcing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Workflow

  • Target Validation and Functional Informatics
  • Lead Identification and Candidate Optimization
  • Preclinical Development
  • Others
  • Target Identification and Screening

By Therapeutic area

  • Cardiovascular
  • Central Nervous System (CNS)
  • Gastrointestinal
  • Others
  • Hematology
  • Respiratory system
  • Infectious disease
  • Oncology
  • Immunology

By Drug Type

  • Small Molecules
  • Large Molecules

By End User

  • Pharmaceutical and Biotechnology companies
  • Academic Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • . Charles River Laboratories,
    • Curia Global Inc
    • Dr. Reddy's Laboratories
    • Dalton Pharma Service
    • Discover X Corporation
    • Laboratory Corporation of America Holdings
    • Merck & Co
    • Syngene International Ltd
    • Thermo Fisher Scientific, Inc.
    • TCG Life Science Pvt. Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Target Identification and Screening
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Target Validation and Functional Informatics
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Lead Identification and Candidate Optimization
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country
  • 4.5 Preclinical Development
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market share analysis by country
  • 4.6 Others
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market share analysis by country

CHAPTER 5: DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Respiratory system
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Infectious disease
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Oncology
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country
  • 5.5 Immunology
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market share analysis by country
  • 5.6 Hematology
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market share analysis by country
  • 5.7 Cardiovascular
    • 5.7.1 Key market trends, growth factors and opportunities
    • 5.7.2 Market size and forecast, by region
    • 5.7.3 Market share analysis by country
  • 5.8 Central Nervous System (CNS)
    • 5.8.1 Key market trends, growth factors and opportunities
    • 5.8.2 Market size and forecast, by region
    • 5.8.3 Market share analysis by country
  • 5.9 Gastrointestinal
    • 5.9.1 Key market trends, growth factors and opportunities
    • 5.9.2 Market size and forecast, by region
    • 5.9.3 Market share analysis by country
  • 6.0 Others
    • 6.0.1 Key market trends, growth factors and opportunities
    • 6.0.2 Market size and forecast, by region
    • 6.0.3 Market share analysis by country

CHAPTER 6: DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Small Molecules
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Large Molecules
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country

CHAPTER 7: DRUG DISCOVERY OUTSOURCING MARKET, BY END USER

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Pharmaceutical and Biotechnology companies
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market share analysis by country
  • 7.3 Academic Institutes
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market share analysis by country
  • 7.4 Others
    • 7.4.1 Key market trends, growth factors and opportunities
    • 7.4.2 Market size and forecast, by region
    • 7.4.3 Market share analysis by country

CHAPTER 8: DRUG DISCOVERY OUTSOURCING MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Workflow
    • 8.2.3 North America Market size and forecast, by Therapeutic area
    • 8.2.4 North America Market size and forecast, by Drug Type
    • 8.2.5 North America Market size and forecast, by End User
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Key market trends, growth factors and opportunities
      • 8.2.6.1.2 Market size and forecast, by Workflow
      • 8.2.6.1.3 Market size and forecast, by Therapeutic area
      • 8.2.6.1.4 Market size and forecast, by Drug Type
      • 8.2.6.1.5 Market size and forecast, by End User
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Key market trends, growth factors and opportunities
      • 8.2.6.2.2 Market size and forecast, by Workflow
      • 8.2.6.2.3 Market size and forecast, by Therapeutic area
      • 8.2.6.2.4 Market size and forecast, by Drug Type
      • 8.2.6.2.5 Market size and forecast, by End User
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Key market trends, growth factors and opportunities
      • 8.2.6.3.2 Market size and forecast, by Workflow
      • 8.2.6.3.3 Market size and forecast, by Therapeutic area
      • 8.2.6.3.4 Market size and forecast, by Drug Type
      • 8.2.6.3.5 Market size and forecast, by End User
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Workflow
    • 8.3.3 Europe Market size and forecast, by Therapeutic area
    • 8.3.4 Europe Market size and forecast, by Drug Type
    • 8.3.5 Europe Market size and forecast, by End User
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Key market trends, growth factors and opportunities
      • 8.3.6.1.2 Market size and forecast, by Workflow
      • 8.3.6.1.3 Market size and forecast, by Therapeutic area
      • 8.3.6.1.4 Market size and forecast, by Drug Type
      • 8.3.6.1.5 Market size and forecast, by End User
      • 8.3.6.2 France
      • 8.3.6.2.1 Key market trends, growth factors and opportunities
      • 8.3.6.2.2 Market size and forecast, by Workflow
      • 8.3.6.2.3 Market size and forecast, by Therapeutic area
      • 8.3.6.2.4 Market size and forecast, by Drug Type
      • 8.3.6.2.5 Market size and forecast, by End User
      • 8.3.6.3 UK
      • 8.3.6.3.1 Key market trends, growth factors and opportunities
      • 8.3.6.3.2 Market size and forecast, by Workflow
      • 8.3.6.3.3 Market size and forecast, by Therapeutic area
      • 8.3.6.3.4 Market size and forecast, by Drug Type
      • 8.3.6.3.5 Market size and forecast, by End User
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Key market trends, growth factors and opportunities
      • 8.3.6.4.2 Market size and forecast, by Workflow
      • 8.3.6.4.3 Market size and forecast, by Therapeutic area
      • 8.3.6.4.4 Market size and forecast, by Drug Type
      • 8.3.6.4.5 Market size and forecast, by End User
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Key market trends, growth factors and opportunities
      • 8.3.6.5.2 Market size and forecast, by Workflow
      • 8.3.6.5.3 Market size and forecast, by Therapeutic area
      • 8.3.6.5.4 Market size and forecast, by Drug Type
      • 8.3.6.5.5 Market size and forecast, by End User
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Key market trends, growth factors and opportunities
      • 8.3.6.6.2 Market size and forecast, by Workflow
      • 8.3.6.6.3 Market size and forecast, by Therapeutic area
      • 8.3.6.6.4 Market size and forecast, by Drug Type
      • 8.3.6.6.5 Market size and forecast, by End User
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Workflow
    • 8.4.3 Asia-Pacific Market size and forecast, by Therapeutic area
    • 8.4.4 Asia-Pacific Market size and forecast, by Drug Type
    • 8.4.5 Asia-Pacific Market size and forecast, by End User
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 Japan
      • 8.4.6.1.1 Key market trends, growth factors and opportunities
      • 8.4.6.1.2 Market size and forecast, by Workflow
      • 8.4.6.1.3 Market size and forecast, by Therapeutic area
      • 8.4.6.1.4 Market size and forecast, by Drug Type
      • 8.4.6.1.5 Market size and forecast, by End User
      • 8.4.6.2 China
      • 8.4.6.2.1 Key market trends, growth factors and opportunities
      • 8.4.6.2.2 Market size and forecast, by Workflow
      • 8.4.6.2.3 Market size and forecast, by Therapeutic area
      • 8.4.6.2.4 Market size and forecast, by Drug Type
      • 8.4.6.2.5 Market size and forecast, by End User
      • 8.4.6.3 Australia
      • 8.4.6.3.1 Key market trends, growth factors and opportunities
      • 8.4.6.3.2 Market size and forecast, by Workflow
      • 8.4.6.3.3 Market size and forecast, by Therapeutic area
      • 8.4.6.3.4 Market size and forecast, by Drug Type
      • 8.4.6.3.5 Market size and forecast, by End User
      • 8.4.6.4 India
      • 8.4.6.4.1 Key market trends, growth factors and opportunities
      • 8.4.6.4.2 Market size and forecast, by Workflow
      • 8.4.6.4.3 Market size and forecast, by Therapeutic area
      • 8.4.6.4.4 Market size and forecast, by Drug Type
      • 8.4.6.4.5 Market size and forecast, by End User
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Key market trends, growth factors and opportunities
      • 8.4.6.5.2 Market size and forecast, by Workflow
      • 8.4.6.5.3 Market size and forecast, by Therapeutic area
      • 8.4.6.5.4 Market size and forecast, by Drug Type
      • 8.4.6.5.5 Market size and forecast, by End User
      • 8.4.6.6 Rest of Asia-Pacific
      • 8.4.6.6.1 Key market trends, growth factors and opportunities
      • 8.4.6.6.2 Market size and forecast, by Workflow
      • 8.4.6.6.3 Market size and forecast, by Therapeutic area
      • 8.4.6.6.4 Market size and forecast, by Drug Type
      • 8.4.6.6.5 Market size and forecast, by End User
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Workflow
    • 8.5.3 LAMEA Market size and forecast, by Therapeutic area
    • 8.5.4 LAMEA Market size and forecast, by Drug Type
    • 8.5.5 LAMEA Market size and forecast, by End User
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Key market trends, growth factors and opportunities
      • 8.5.6.1.2 Market size and forecast, by Workflow
      • 8.5.6.1.3 Market size and forecast, by Therapeutic area
      • 8.5.6.1.4 Market size and forecast, by Drug Type
      • 8.5.6.1.5 Market size and forecast, by End User
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Key market trends, growth factors and opportunities
      • 8.5.6.2.2 Market size and forecast, by Workflow
      • 8.5.6.2.3 Market size and forecast, by Therapeutic area
      • 8.5.6.2.4 Market size and forecast, by Drug Type
      • 8.5.6.2.5 Market size and forecast, by End User
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Key market trends, growth factors and opportunities
      • 8.5.6.3.2 Market size and forecast, by Workflow
      • 8.5.6.3.3 Market size and forecast, by Therapeutic area
      • 8.5.6.3.4 Market size and forecast, by Drug Type
      • 8.5.6.3.5 Market size and forecast, by End User
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Key market trends, growth factors and opportunities
      • 8.5.6.4.2 Market size and forecast, by Workflow
      • 8.5.6.4.3 Market size and forecast, by Therapeutic area
      • 8.5.6.4.4 Market size and forecast, by Drug Type
      • 8.5.6.4.5 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 . Charles River Laboratories,
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 Curia Global Inc
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 Dr. Reddy's Laboratories
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 Dalton Pharma Service
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Discover X Corporation
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 Laboratory Corporation of America Holdings
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Merck & Co
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Syngene International Ltd
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 Thermo Fisher Scientific, Inc.
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments
  • 10.10 TCG Life Science Pvt. Ltd
    • 10.10.1 Company overview
    • 10.10.2 Company snapshot
    • 10.10.3 Operating business segments
    • 10.10.4 Product portfolio
    • 10.10.5 Business performance
    • 10.10.6 Key strategic moves and developments